Glenmede Trust Co. NA increased its stake in Gilead Sciences (NASDAQ:GILD) by 3.8% in the 4th quarter, HoldingsChannel reports. The fund owned 647,257 shares of the biopharmaceutical company’s stock after acquiring an additional 23,751 shares during the period. Glenmede Trust Co. NA’s holdings in Gilead Sciences were worth $46,368,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. Vident Investment Advisory LLC boosted its holdings in Gilead Sciences by 40.5% during the fourth quarter. Vident Investment Advisory LLC now owns 68,800 shares of the biopharmaceutical company’s stock worth $4,929,000 after buying an additional 19,833 shares in the last quarter. Financial Advocates Investment Management bought a new stake in Gilead Sciences during the fourth quarter worth approximately $607,000. Laurel Wealth Advisors Inc. boosted its holdings in Gilead Sciences by 12.5% during the fourth quarter. Laurel Wealth Advisors Inc. now owns 9,726 shares of the biopharmaceutical company’s stock worth $696,000 after buying an additional 1,080 shares in the last quarter. Hoylecohen LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $6,202,000. Finally, Platinum Investment Management Ltd. boosted its holdings in Gilead Sciences by 5.0% during the fourth quarter. Platinum Investment Management Ltd. now owns 3,044,930 shares of the biopharmaceutical company’s stock worth $218,138,000 after buying an additional 145,300 shares in the last quarter. Institutional investors and hedge funds own 78.35% of the company’s stock.
A number of research firms recently commented on GILD. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $79.02 to $96.00 in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $88.65.
GILD stock opened at $73.70 on Monday. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The company has a market capitalization of $96,093.74, a price-to-earnings ratio of 8.61, a P/E/G ratio of -1.67 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company’s revenue was down 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.70 EPS. research analysts expect that Gilead Sciences will post 6.32 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a dividend of $0.57 per share. The ex-dividend date was Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.09%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.
In other news, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction on Friday, April 13th. The shares were sold at an average price of $75.56, for a total transaction of $440,741.48. Following the transaction, the director now owns 58,452 shares in the company, valued at approximately $4,416,633.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gayle E. Wilson sold 60,000 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the transaction, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. Insiders have sold a total of 308,600 shares of company stock worth $24,328,226 in the last 90 days. 1.30% of the stock is owned by insiders.
WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/23/gilead-sciences-gild-stake-lifted-by-glenmede-trust-co-na.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.